Allorion Therapeutics
Latest round
- Series B
Last raised
- Mar 2023
Total raised
- $90M
Investors
- 10
About Allorion Therapeutics
Based in Guangzhou, China, and established in 2020, Allorion Therapeutics Inc. is a drug development that focuses on developing the next generation of targeted drugs for cancer and autoimmune diseases. The company team is comprised of experts in cancer biology and drug development. It has dual sites operating in Natick, Massachusetts, and Guangzhou, China. As of 2023, the company has 53 employees. Gregory Berk, Chief Medical Officer of the company, has served as the clinical senior vice president and chief medical officer of many well-known biotechnology and biomedical companies in the United States. The company-developed fields include selecting validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of action, building data, and screening platforms, constructing and optimizing chemical libraries with allosteric and covalent modulators. Its main products include TYK2ARTS-011 and CDK2ARTS-021, etc. The company's products are used in diseases such as cancer and tumors.
Who invested in Allorion Therapeutics
10 investors across 2 rounds
See all investors in Allorion Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Allorion Therapeutics
Who invested in Allorion Therapeutics?
Allorion Therapeutics has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Allorion Therapeutics raised?
Allorion Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Allorion Therapeutics last raise money?
Allorion Therapeutics's most recent round on record is a Series B, in Mar 2023.
What does Allorion Therapeutics do?
Based in Guangzhou, China, and established in 2020, Allorion Therapeutics Inc.
Where is Allorion Therapeutics headquartered?
Allorion Therapeutics is headquartered in Guangzhou, China.
Which VCs invest in companies like Allorion Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Allorion Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Allorion Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.